Acute Lymphoblastic Leukemia | Topics

Application for Brexucabtagene Autoleucel in B-cell ALL Submitted to FDA for Consideration
April 09, 2021

CD19-directed CAR T-cell therapy brexucabtagene autoleucel will be considered by FDA for indication in adults with B-cell precursor acute lymphoblastic leukemia.

Treatment Timing and Other Prognostic Factors Associated With Reduction in CNS Relapse Risk for Pediatric ALL
April 06, 2021

A study conducted across 20 medical centers and hospitals in China concluded that treatment timing, total intravenous anesthesia, and flow cytometry were associated with a reduced risk of central nervous system relapse for pediatric patients with acute lymphoblastic leukemia.

Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL
March 29, 2021

Follow-up of 4.8 years to a phase 1 trial demonstrated that deep and durable responses are attainable in a large cohort of children and young adult patients with B-cell acute lymphoblastic leukemia who were treated with CD19-directed CAR T-cell therapy followed by allogeneic hematopoietic stem cell transplantation.